BEAM · Beam Therapeutics Inc
United States · RS rating 27 · As of 2026-10-14
| Price | 23.65 USD |
|---|---|
| 1-day change | -3.2% |
| RS rating (overall / 1M / 3M / 12M) | 27 / 80 / 22 / 35 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 44 / 21 / 51 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +311.8% |
| Sales growth Q/Q | +1076.6% |
| Distance from 52-week high | +37.6% |
| Market cap (USD) | $3.1B |